On the public citation graph

Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis

https://doi.org/10.1101/813907
0 signed · 32 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/path.4808openalex-snapshot
The extracellular matrix – the under‐recognized element in lung disease?
inferredcites →https://doi.org/10.1007/s11010-007-9595-2openalex-snapshot
Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy
inferredcites →https://doi.org/10.1016/j.ajpath.2017.12.020openalex-snapshot
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice
inferredcites →https://doi.org/10.1016/j.jhep.2005.02.052openalex-snapshot
Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2
inferredcites →https://doi.org/10.1016/s2213-2600(16)30421-0openalex-snapshot
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
inferredcites →https://doi.org/10.1021/acs.jmedchem.7b00345openalex-snapshot
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)
inferredcites →https://doi.org/10.1021/acs.jmedchem.9b01112openalex-snapshot
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth
inferredcites →https://doi.org/10.1038/jhg.2016.99openalex-snapshot
Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.1038/ncomms13710openalex-snapshot
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment
inferredcites →https://doi.org/10.1038/nm.2208openalex-snapshot
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
inferredcites →https://doi.org/10.1038/nrm3904openalex-snapshot
Remodelling the extracellular matrix in development and disease
inferredcites →https://doi.org/10.1038/s41598-017-00270-0openalex-snapshot
Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis
inferredcites →https://doi.org/10.1074/jbc.m109.094136openalex-snapshot
Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor
inferredcites →https://doi.org/10.1074/jbc.m111.261016openalex-snapshot
The Enzymatic Activity of Lysyl Oxidas-like-2 (LOXL2) Is Not Required for LOXL2-induced Inhibition of Keratinocyte Differentiation
inferredcites →https://doi.org/10.1080/1061186x.2018.1550649openalex-snapshot
LOX/LOXL in pulmonary fibrosis: potential therapeutic targets
inferredcites →https://doi.org/10.1093/carcin/bgt241openalex-snapshot
Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours
inferredcites →https://doi.org/10.1111/ajt.14103openalex-snapshot
Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis
inferredcites →https://doi.org/10.1126/scitranslmed.3001510openalex-snapshot
TLR9 Differentiates Rapidly from Slowly Progressing Forms of Idiopathic Pulmonary Fibrosis
inferredcites →https://doi.org/10.1136/gutjnl-2016-312473openalex-snapshot
Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
inferredcites →https://doi.org/10.1158/0008-5472.can-15-2813openalex-snapshot
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-3096openalex-snapshot
LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
inferredcites →https://doi.org/10.1164/rccm.201707-1519ocopenalex-snapshot
Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis
inferredcites →https://doi.org/10.1167/iovs.13-11696openalex-snapshot
The Role of LOX and LOXL2 in Scar Formation After Glaucoma Surgery
inferredcites →https://doi.org/10.1167/iovs.14-15513openalex-snapshot
The Role of LOX and LOXL2 in the Pathogenesis of an Experimental Model of Choroidal Neovascularization
inferredcites →https://doi.org/10.1183/09031936.00141013openalex-snapshot
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
inferredcites →https://doi.org/10.1242/dmm.004077openalex-snapshot
Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer
inferredcites →https://doi.org/10.1242/dmm.030114openalex-snapshot
Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis
inferredcites →https://doi.org/10.18632/oncotarget.17114openalex-snapshot
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
inferredcites →https://doi.org/10.3390/ijms20071634openalex-snapshot
LOXL2—A New Target in Antifibrogenic Therapy?

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1042/cs20190893openalex-snapshot
Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases
inferred← citeshttps://doi.org/10.1080/14728222.2021.2006186openalex-snapshot
Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications
inferred← citeshttps://doi.org/10.23866/brnrev:2020-0012openalex-snapshot
Mechanotherapeutics for the Treatment of Idiopathic Pulmonary Fibrosis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.